Giving another chance to mifepristone in pharmacotherapy for aggressive meningiomas—A likely synergism with hydroxyurea?

Meningiomas are the most frequently reported intracranial tumors, accounting for approximately one-fourth of all reported primary brain neoplasms.1 They are benign in approximately 90% of the cases and the remaining cases are either borderline or atypical (World Health Organization [WHO] grade II) or malignant (WHO grade III).1 In the United States, the incidence rates with similar age standardization estimated from figures provided by the Central Brain Tumor Registry were 1.8 for men and 4.2 per 100,000 for women in 2006.

Source: Current Problems in Cancer - May 15, 2016 Category: Cancer & Oncology Authors: İlhan Elmaci, Meric A. Altinoz, Aydin Sav, Zeliha Yazici, Aysel Ozpinar Source Type: research